Baird’s Kite Pharma, Inc. KITE Stock Holding History

Baird’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$1.35M	Buy	+23,356	New	+$1.57M	0.01%	667

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Baird's KITE Position: Q1 2015 in Review

Baird opened a new position in Kite Pharma, Inc. (KITE) in Q1 2015: 23,356 shares worth $1.35M. The stake represents 0.01% of the portfolio and ranks #667 among its holdings.

148 funds tracked by Wall St. Rank hold KITE as of Q1 2015.

Baird held 23,356 shares of Kite Pharma, Inc. worth $1.35M as of Q1 2015.
Kite Pharma, Inc. was a new Baird position in Q1 2015.
Kite Pharma, Inc. made up 0.01% of Baird's portfolio in Q1 2015, its #667 holding.
148 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.